卫信康涨2.09%，成交额601.80万元，主力资金净流入46.92万元

Group 1 - The core viewpoint of the news is that Weixin Kang's stock price has shown a slight increase of 2.09% this year, but has experienced declines over the past five, twenty, and sixty trading days [2] - As of January 5, Weixin Kang's stock price reached 10.74 yuan per share, with a total market capitalization of 4.674 billion yuan [1] - The company has seen a net inflow of main funds amounting to 46.92 thousand yuan, with large single purchases accounting for 13.15% of total transactions [1] Group 2 - Weixin Kang's main business involves the research, production, and sales of chemical drug formulations and their raw materials, with a revenue composition of 72.08% from market services and 27.92% from pharmaceuticals [2] - As of September 30, the number of Weixin Kang's shareholders increased by 14.14% to 16,500, while the average circulating shares per person decreased by 12.39% to 26,333 shares [2] - For the period from January to September 2025, Weixin Kang reported an operating income of 862 million yuan, a year-on-year decrease of 13.27%, and a net profit attributable to shareholders of 219 million yuan, down 9.90% year-on-year [2] Group 3 - Weixin Kang has distributed a total of 624 million yuan in dividends since its A-share listing, with 438 million yuan distributed over the past three years [3] - As of September 30, 2025, several institutions have exited the top ten circulating shareholders, including Guangfa Medical Health Stock A and Xinao Small and Medium Cap Mixed A [3]